- Home
- TCBK vs EWTX Comparison
TCBK vs EWTX Comparison
Compare TCBK & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCBK
- EWTX
- Stock Information
- Founded
- TCBK 1975
- EWTX 2017
- Country
- TCBK United States
- EWTX United States
- Employees
- TCBK N/A
- EWTX N/A
- Industry
- TCBK Major Banks
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- TCBK Finance
- EWTX Health Care
- Exchange
- TCBK Nasdaq
- EWTX Nasdaq
- Market Cap
- TCBK 1.4B
- EWTX 1.5B
- IPO Year
- TCBK N/A
- EWTX 2021
- Fundamental
- Price
- TCBK $42.32
- EWTX $13.64
- Analyst Decision
- TCBK Buy
- EWTX Buy
- Analyst Count
- TCBK 6
- EWTX 9
- Target Price
- TCBK $47.80
- EWTX $39.89
- AVG Volume (30 Days)
- TCBK 104.3K
- EWTX 745.9K
- Earning Date
- TCBK 07-28-2025
- EWTX 08-07-2025
- Dividend Yield
- TCBK 3.10%
- EWTX N/A
- EPS Growth
- TCBK 4.60
- EWTX N/A
- EPS
- TCBK 3.43
- EWTX N/A
- Revenue
- TCBK $389,795,000.00
- EWTX N/A
- Revenue This Year
- TCBK $7.08
- EWTX N/A
- Revenue Next Year
- TCBK $5.38
- EWTX N/A
- P/E Ratio
- TCBK $12.41
- EWTX N/A
- Revenue Growth
- TCBK 1.12
- EWTX N/A
- 52 Week Low
- TCBK $35.20
- EWTX $10.60
- 52 Week High
- TCBK $51.06
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- TCBK 57.54
- EWTX 48.65
- Support Level
- TCBK $39.69
- EWTX $13.30
- Resistance Level
- TCBK $43.08
- EWTX $14.08
- Average True Range (ATR)
- TCBK 1.20
- EWTX 0.55
- MACD
- TCBK -0.02
- EWTX 0.10
- Stochastic Oscillator
- TCBK 81.46
- EWTX 71.51
About TCBK TriCo Bancshares
TriCo Bancshares is a California corporation organized to act as a bank holding company for Tri Counties Bank. The Bank is a California-chartered bank that is engaged in the general commercial and retail banking business in California counties. The Bank provides a breadth of personal, small business, and commercial financial services, including accepting demand, savings and time deposits and making small business, commercial, real estate, and consumer loans, as well as a range of treasury management services and other customary banking services including safe deposit boxes at some branches. The company's primary source of revenue is the net interest income.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.